Rakovina Therapeutics continues to make progress as company provides corporate update
–News Direct– Rakovina Therapeutics Executive Chairman Jeffery Bacha joined Steve Darling from Proactive to discuss the company's corporate highlights as part of its second-quarter financial report. Bacha highlighted several significant developments for the company during this period: including a publication in the Journal of Clinical Oncology. Rakovina Therapeutics published a paper in the Journal of Clinical Oncology describing pre-clinical data for its lead pre-clinical candidate, kt-3283. This data demonstrates the potential of kt-3283 to treat cancers that are resistant to
Read more